Epigral Ltd

In a regulatory filing, the company said that Jain's resignation will be effective from the close of business hours on 30 September 2025. Epigral is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The company's consolidated net profit surged 87.1% to Rs 160.69 crore despite 6.9% decline in revenue from operations to Rs 606.54 crore in Q1 FY26 over Q1 FY25. Shares of Epigral shed 0.67% to Rs 1,785 on the BSE. Powered by Capital Market - Live

Net profit of Epigral rose 87.13% to Rs 160.69 crore in the quarter ended June 2025 as against Rs 85.87 crore during the previous quarter ended June 2024. Sales declined 6.86% to Rs 606.54 crore in the quarter ended June 2025 as against Rs 651.20 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales606.54651.20 -7 OPM %26.9427.07 - PBDT148.55164.41 -10 PBT107.01130.96 -18 NP160.6985.87 87 Powered by Capital Market - Live

Epigral will hold a meeting of the Board of Directors of the Company on 2 August 2025.Powered by Capital Market - Live

Epigral announced that the Annual General Meeting(AGM) of the company will be held on 28 June 2025.Powered by Capital Market - Live

Epigral as on today 04 June 2025 has executed (I) Share Subscription and Shareholder's Agreement with Prozeal Green Power (Promoter) and Pro-Zeal Green Power Ten (Power Producer) and (II) Energy Supply Agreement with 'Pro-Zeal Green Power Ten to source a contracted capacity of 19.80 MW 'Wind Solar Hybrid (WSH) Power' (Project) as a Captive Consumer from WSH power plant located in the State of Gujarat. This transaction entails subscription of minimum 26% of Securities (Equity and Optionally Convertible Debentures, in one or more tranches) of Power Producer, a Special Purpose Vehicle (SPV) formed for developing, constructing, operating and maintaining the said Project. Sourcing power from renewable resources is in line with the Company's commitment towards sustainability goals. Powered by Capital Market - Live

Epigral has fixed 21 June 2025 as record date for payment of final dividend. Powered by Capital Market - Live

Net profit of Epigral rose 12.45% to Rs 86.89 crore in the quarter ended March 2025 as against Rs 77.27 crore during the previous quarter ended March 2024. Sales rose 19.63% to Rs 627.63 crore in the quarter ended March 2025 as against Rs 524.63 crore during the previous quarter ended March 2024. For the full year,net profit rose 82.62% to Rs 357.69 crore in the year ended March 2025 as against Rs 195.87 crore during the previous year ended March 2024. Sales rose 32.19% to Rs 2550.13 crore in the year ended March 2025 as against Rs 1929.19 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales627.63524.63 20 2550.131929.19 32 OPM %27.6229.62 -27.8724.94 - PBDT165.28143.83 15 673.65414.31 63 PBT131.33113.45 16 541.09290.75 86 NP86.8977.27 12 357.69195.87 83 Powered by Capital Market - Live

Epigral announced that the Board of Directors of the Company at its meeting held on 5 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Epigral will hold a meeting of the Board of Directors of the Company on 5 May 2025.Powered by Capital Market - Live

The agency has reaffirmed its 'Crisil A1+' rating on the short-term bank facilities of Epigral. Crisil Ratings stated that the rating action reflects sustenance of the strong business risk profile of Epigral, supported by its continued focus on speciality and derivative business (54% share in revenue in the first nine months of fiscal 2025, compared with 42% in the corresponding period of previous fiscal and 30% in fiscal 2023), that is expected to improve further and contribute to around two-third of the revenue over the next two to three fiscals. The revenue grew 37% on-year to Rs 1,923 crore in the first nine months of fiscal 2025, driven by volume growth of 15%, majorly from the derivatives and speciality business. The revenue is expected to grow at a similar rate in fiscal 2025, with the expectation of the second half remaining stronger compared with the first half on account of seasonal demand for the key products namely, chlorinated polyvinyl chloride (CPVC) and epichlorohydrin (ECH). Epigral's EBITDA margin increased to 28% in the first nine months of fiscal 2025 from 23.5% in the first nine months of fiscal 2024 (24.9% in fiscal 2024), due to continued focus on value-added offerings, and is expected at 27-28% in fiscal 2025. Furthermore, the rating action also factors in sustenance of the strong financial risk profile. Epigral has strengthened its balance sheet by the recent equity raise of Rs 333 crore via qualified institutional placement (QIP) and majorly utilised the proceeds towards the retirement of debt, leading to overall debt declining to Rs 570 crore as on 31 December 2024 from Rs 895 crore as on 30 September 2024. The return on capital employed (RoCE) stood at 16.2% in fiscal 2024 and is expected to be around 22% in fiscal 2025. These strengths are partially offset by the company's high albeit reducing dependence on the intensely competitive chlor alkali industry, exposure to regulatory risks, vulnerability of the operating margin to fluctuations in caustic soda prices and exposure to project implementation risks. Epigral is a leading integrated manufacturer of chemicals in India. Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC, in India. Along with ECH and CPVC, Epigral is a leading manufacturer of caustic soda, caustic potash, chloromethanes, hydrogen peroxide, chlorine and hydrogen. Powered by Capital Market - Live